A novel implantable therapy that works directly on the nerves affected during prostate cancer surgery, to help restore natural erectile function when medications aren't enough. CaverSTIM™ is currently in clinical trials at leading research centers across the world.
CaverSTIM™ is designed to address nerve-related erectile challenges with precision and purpose
Directly supports cavernous nerve function rather than just managing symptoms.
Intervenes during the critical post-surgical window when nerve recovery potential is highest.
Engineered to integrate smoothly into existing prostate cancer surgery workflows, adding no additional procedural complexity for surgeons or care teams.
No daily medications, pumps, or ongoing pharmaceutical interventions required.
Learn more about how our technology works
CaverSTIM™ introduces a new way of addressing erectile dysfunction after prostate cancer surgery by intervening early, at the point when nerve recovery is still possible. Instead of managing symptoms years later, the device is designed for placement during the primary surgical procedure, when targeted support can have the greatest impact.
By delivering focused neuromodulation during the critical post-operative healing period, CaverSTIM™ is engineered to help maintain and restore natural pelvic nerve function, with the goal of improving long-term erectile outcomes.
The system includes three coordinated components: an implantable electrode array placed during surgery, a subcutaneous pulse generator, and a clinician-controlled external programming interface.
.png)
Built on proven neuromodulation principles, CaverSTIM™ uses precisely calibrated electrical stimulation to support nerve activity in the cavernous nerves—the key pathways responsible for erectile function.
The system features:
CaverSTIM™ consists of three integrated components designed to work together to support nerve function recovery:
Placed during surgery to align with nerve pathways, no additional procedure needed.
A small, rechargeable unit placed under the skin, programmed by clinicians and tailored to patient needs.
Stimulation begins shortly after surgery, aligning with critical windows for nerve recovery.
A step-by-step look at the CaverSTIM™ treatment pathway
During prostate cancer surgery, the electrode array is placed adjacent to the cavernous nerve bundles as part of the normal surgical workflow. The placement integrates seamlessly into the procedure and does not require additional incisions or invasive steps beyond the standard operation.
After an initial post-operative healing period, the clinical team activates the subcutaneous pulse generator. Stimulation settings are tailored to each patient, informed by surgical findings and individual nerve response.
CaverSTIM™ provides programmed neuromodulation over the course of several weeks to months, delivering consistent support during the key period of nerve healing and regeneration. The stimulation schedule is optimized to reinforce natural nerve signaling as recovery progresses.
Regular follow-up sessions enable clinicians to evaluate nerve recovery, track patient progress, and adjust stimulation settings as needed. The wireless programming interface allows for precise, non-invasive parameter adjustments to help optimize each patient's therapeutic response.
CaverSTIM™ is being evaluated through a multi-stage clinical development program designed to assess safety, feasibility, and potential benefit in restoring erectile nerve function after prostate cancer surgery. Our global studies follow rigorous scientific and regulatory standards to build a strong foundation for future approval.
CaverSTIM™ is an investigational device and is not approved for commercial use. Safety and efficacy have not yet been established.
Whether you're a healthcare provider, researcher, or patient seeking information about CaverSTIM™, we're here to help. Connect with our team to discuss clinical trials, research opportunities, or general inquiries.
Comphya is a Swiss clinical-stage medical device company developing CaverSTIM™, an implantable neuromodulation system intended to support nerve function following radical prostatectomy.